

# **ASTRAZENECA PLC**

## **Interim Financial Statements**

**30 JUNE 2005**

Registered number : 2723534



# ASTRAZENECA PLC

## PROFIT AND LOSS ACCOUNT

for the period ended 30 June 2005

	Notes	30 June 2005 \$m	31 December 2004 (Restated) \$m
Turnover		-	-
Operating costs		(3)	(9)
<b>Operating loss</b>		(3)	(9)
Income from shares in subsidiary undertakings		-	5
<b>Loss on ordinary activities before interest</b>		(3)	(4)
Net interest and exchange gains/(losses)	2	(18)	388
<b>Profit/(loss) on ordinary activities before taxation</b>		(21)	384
Taxation		(12)	506
<b>Net profit/(loss) for the year</b>		(33)	890
Dividends to Shareholders	3	(1,061)	(1,408)
<b>Loss retained for the year</b>		(1,094)	(518)

## STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES

for the period ended 30 June 2005

Apart from the gains and losses reported above, the Company has recorded a gain of \$282m in respect of the tax settlement of an unrealised exchange loss in the year ended 31 December 2004.

# ASTRAZENECA PLC

## BALANCE SHEET

As at 30 June 2005 and 31 December 2004


	Notes	30 June 2005 \$m	31 December 2004 (Restated) \$m
<b>Fixed assets</b>			
Fixed asset investments	4	7,745	7,745
<b>Current assets</b>			
External debtors - other		46	25
Debtors - amounts owed by subsidiaries		21,548	23,228
		21,594	23,253
<b>Total assets</b>		29,339	30,998
<b>Creditors due within one year</b>			
Short-term borrowings		(9)	(4)
Other creditors		(123)	(116)
Amounts owed to subsidiaries		(2,980)	(2,409)
		(3,112)	(2,529)
<b>Net current assets</b>		18,482	20,724
<b>Total assets less current liabilities</b>		26,227	28,469
<b>Creditors due after more than one year</b>			
Loans		(1,030)	(1,030)
<b>Net assets</b>		25,197	27,439
<b>Capital and reserves</b>			
Called-up share capital	5	404	411
Share premium account	6	584	550
Capital redemption reserve	6	43	36
Other reserves	6	1,841	1,841
Profit and loss account	6	22,325	24,601
<b>Shareholders' funds - equity interests</b>	7	25,197	27,439

The interim financial statements on pages 1 to 5 were approved by the Board of Directors on 28 July 2005 and were signed on its behalf by:

Sir Tom McKillop  
Director



Jonathan Symonds  
Director



# ASTRAZENECA PLC

## NOTES RELATING TO THE FINANCIAL STATEMENTS

### 1 Basis of presentation of financial information

The AstraZeneca PLC interim financial statements are presented in accordance with the accounting policies set out in the 2004 annual accounts except that, during the period, the Company adopted the provisions of Financial Reporting Standards No.20 "Share-based Payments", No.21 "Events after the Balance Sheet Date", No.23 "The Effects of Changes in Foreign Exchange Rates", No.24 "Financial Reporting in Hyperinflationary Economies", No.25 "Financial Instruments: Disclosure and Presentation" and No.26 "Financial Instruments: Measurement". The adoption of these FRSs had no effect on the accounting policies, net assets or results of the Company, except for FRS21. Under FRS21, proposed dividends are no longer accrued in the balance sheet – accordingly, the net assets at 31 December 2004 were increased by \$1,061m.

These interim financial statements do not constitute statutory accounts of the Company within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2004 have been filed with the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

### 2 Net interest and exchange gains/(losses)

	30 June 2005 \$m	31 December 2004 \$m
<b>Interest payable and similar charges</b>		
Payable to subsidiary undertakings	(10)	(22)
External interest payable	(20)	(25)
Net exchange gains/(losses)	(19)	37
	(49)	(10)
<b>Interest receivable and similar income</b>		
Receivable from subsidiary undertakings	31	398
<b>Net interest and exchange gains/(losses)</b>	(18)	388

## NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

### 3 Dividends to Shareholders

	30 June 2005 cents per 25c Share	31 Dec 2004 cents per 25c Share	30 June 2005 \$m	31 Dec 2004 (restated) \$m
1 <sup>st</sup> interim	-	29.5	-	494
2 <sup>nd</sup> interim/final	64.5	54.0	1,061	914
	64.5	83.5	1,061	1,408

Subsequent to the period end, on the 28 July the Board declared an interim 2005 dividend of 38 cents per share (\$615m).

### 4 Fixed Asset Investments

	Shares \$m	Loans \$m	Total \$m
<b>Cost</b>			
At beginning of period	6,715	1,030	7,745
Additions	-	-	-
Disposals and other movements	-	-	-
<b>At end of period</b>	6,715	1,030	7,745

### 5 Called-up share capital

	Authorised	Allotted, called-up and fully paid	
	30 June 2005 \$m	30 June 2005 \$m	31 December 2004 \$m
Ordinary Shares (\$0.25 each)	411	404	411
Unissued Ordinary Share (\$0.25 each)	189	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	404	411

The movements in share capital during the period can be summarised as follows:

	No of shares (million)	\$m
At beginning of period	1,645	411
Issue of shares	1	-
Repurchase of shares	(29)	(7)
<b>At end of period</b>	1,617	404

## NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

### 6 Reserves

	Share Premium Account	Capital Redemption Reserve	Other Reserves	Profit and Loss Account (restated)	Total 30 June 2005	Total 31 Dec 2004 (restated)
	\$m	\$m	\$m	\$m	\$m	\$m
At beginning of period	550	36	1,841	24,601	27,028	29,362
Net losses for the period	-	-	-	(33)	(33)	1,172
Dividends	-	-	-	(1,061)	(1,061)	(1,408)
Share repurchase	-	7	-	(1,182)	(1,175)	(2,199)
Share premiums	34	-	-	-	34	101
At end of period	584	43	1,841	22,325	24,793	27,028
Distributable reserves at end of period	-	-	625	1,027	1,652	2,269

At 30 June 2005 \$21,298m (31 December 2004 : \$22,923m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During 2005 \$1,625m of the profit was realised by repayment. Subsequent to the period end a further \$2,989m was repaid on 19<sup>th</sup> July 2005. After accounting for the interim dividend of \$615m the resulting net increase in additional distributable reserves not included in the figures above is \$2,374m. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

### 7 Reconciliation of movements in shareholders' funds

	30 June 2005	31 December 2004 (Restated)
	\$m	\$m
Net gains/(losses) for the financial period	(33)	1,172
Dividends	(1,061)	(1,408)
	(1,094)	(236)
Issues of AstraZeneca Ordinary Shares	34	102
Repurchase of AstraZeneca Ordinary Shares	(1,182)	(2,212)
Net reduction to shareholders' funds	(2,242)	(2,346)
Shareholders' funds at beginning of period	27,439	29,785
Shareholders' funds at end of period	25,197	27,439